Associations of folic acid supplementation with risk of preterm birth (PTB) and small-for-gestational-age (SGA) birth were unclear for the Chinese populations. The aim of the present study was to investigate the associations in a large Chinese prospective cohort study: the Jiaxing Birth Cohort. In the Jiaxing Birth Cohort, 240 954 pregnant women visited local clinics or hospitals within their first trimester in Southeast China during 1999-2012. Information on anthropometric parameters, folic acid supplementation and other maternal characteristics were collected by in-person interviews during their first visit. Pregnancy outcomes were recorded during the follow-up of these participants. Multinomial logistic regression was used to examine the association of folic acid supplementation with pregnancy outcomes. The prevalence of folic acid supplementation was 24·9 % in the cohort. The prevalence of PTB and SGA birth was 3·48 and 9·2 %, respectively. Pre-conceptional folic acid supplementation was associated with 8 % lower risk of PTB (relative risk (RR) 0·92; 95 % CI 0·85, 1·00; P = 0·04) and 19 % lower risk of SGA birth (RR 0·81; 95 % CI 0·70, 0·95; P = 0·008), compared with non-users. Higher frequency of pre-conceptional folic acid use was associated with lower risk of PTB (P trend = 0·032) and SGA birth (P trend = 0·046). No significant association between post-conceptional initiation of folic acid supplementation and either outcome was observed. In conclusion, the present study suggests an association between pre-conceptional, but not post-conceptional, folic acid supplementation and lower risk of PTB and SGA birth in the Jiaxing Birth Cohort. Further research in other cohorts of large sample size is needed to replicate these findings.
Folate is a water-soluble B vitamin, playing a critical role in the one-carbon metabolism process, which is essential for DNA synthesis, repair and methylation (1) . It is also important for periods of rapid cell division and growth, which occur during pregnancy and infancy (1) (2) (3) . Pregnant women may be at higher risk of folate deficiency compared with non-pregnant women, as the folate requirement is 5-to 10-fold higher during pregnancy (3) . It has been well accepted that maternal folate status is protectively associated with neural tube defects (4, 5) and other congenital disorders (6, 7) . However, the associations of folate supplementation with other pregnancy outcomes such as preterm birth (PTB) or small-for-gestational-age (SGA) birth are still inconclusive (8) (9) (10) (11) (12) (13) (14) (15) (16) . Some observational studies suggest a protective association of folate supplementation with the risk of PTB or SGA birth (9, 10, 12, 14) , whereas others have not found such a protective association (15, 16) . Results from randomised controlled trials also show conflicting results (13) . In 2009, free folic acid supplements (400 mg/d) were given to rural women of child-bearing age across China as a policy issued by the Ministry of Health in China. Although numerous observational studies or randomised trials have reported the association between folic acid supplementation and PTB or SGA, studies based on Chinese populations are still limited (17, 18) . A prospective cohort study conducted in central China, involving 4448 participants, suggested that folic acid supplementation is associated with lower risk of SGA birth (17) . Another large Chinese cohort study indicated that peri-conceptional folic acid supplementation was inversely associated with risk of PTB (18) . However, all the participants included in this large cohort were recruited 20 years ago (in mid 1990s). In addition, only the association of folic acid supplementation with PTB was investigated, and the potential dose-response relationship was not examined (18) .
More updated and larger prospective cohort studies are warranted to comprehensively explore these associations in Chinese populations. The aim of the present study was to examine the association between folic acid supplementation and risk of PTB and SGA birth, as well as potential doseresponse relationships in a large Chinese cohort, involving 240 954 participants, during 1999-2012.
Methods

Study population
The present population-based prospective cohort study was based on a birth defect surveillance system in China, initiated in 1993 (19) . During 1999-2012, 240 954 pregnant women visited local clinics and hospitals within their first trimester in Southeast China, Jiaxing area of Zhejiang Province, and were enrolled in the 'Jiaxing Birth Cohort'. Information on anthropometric parameters, folic acid supplementation and other maternal characteristics was collected by in-person interviews during their first visit to the clinics or hospitals. Subjects were excluded if they gave multiple births or non-live births (n 2086), reported any missing information on folic acid supplementation (n 5531), had missing data on the child's sex (n 119), had extreme values of maternal age (<16 or >50 years) (n 36), extreme gestational age (<28 or >42 weeks) (n 1566) or gave birth to children with extreme birth weight (<1000 or >5000 g) (n 382); subjects with extreme menarcheal age (<10 or >20 year) were also excluded (n 55). Finally, 231 179 participants were eligible for the statistical analysis.
The study was conducted according to principles laid down in the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of the College of Biosystem Engineering & Food Science at Zhejiang University, China. All the participants gave their oral informed consent.
Folic acid supplementation and pregnancy outcomes
Folic acid supplementation status was assessed by three questions during an interview. (1) Have they ever taken folic acid supplements during this pregnancy (yes or no); (2) did they start taking the folic acid supplements before or after conception; (3) if they took folic acid supplements, how often did they take the pills: occasionally (<15 capsules/month), sometimes (15-25 capsules/month) or often (≥25 capsules/ month). Pre-and post-conceptional folic acid supplementation was defined when participants started taking folic acid before and after conception, respectively. The mean gestational age for the time of the interview was 9·5 (SD 2·2) weeks.
PTB was defined as delivery before gestational week 37. Gestational age was calculated based on the self-reported 1st day of the woman's last normal menstrual period. SGA birth was determined as the birth weight below the 10th percentile for the gestational age, based on a global reference for fetal weight and birth weight percentiles by Mikolajczyk et al. (20) . The local weight percentiles across different gestational ages were obtained when the mean birth weight at 40 weeks and standard deviation of birth weight for the present population were entered into the excel-based calculator derived from the study by Mikolajczyk et al. (20) . Birth weight was measured to the nearest 0·01 kg by trained nurses right after the infant was born.
Covariates
Maternal educational status was categorised as > high school, high school and < high school, and occupation was categorised into four groups: farm work, routine job, temporary job and unemployed. Maternal smoking status was defined as current smoker v. non-current smoker, and alcohol drinking status was defined as current drinker v. non-current drinker. Maternal parity status was defined as primiparous or multiparous.
Maternal age, BMI and menarcheal age were used as continuous variables in the statistical models, except when they were used to describe the population characteristics. Recruiting before or after 2010 (<2010 v. ≥2010) was also considered as a confounder, as folic acid supplements became freely available in China for rural women of pregnancy age in late 2009. Since then, the prevalence of folic acid supplementation increased significantly in the population. This new policy dramatically changed the pattern of folic acid supplementation among women, which may be associated with some unknown confounding factors.
Statistical analysis
Multinomial logistic regression was used to examine the relationship between folic acid supplementation and risk of PTB and SGA birth. Within these statistical models, potential covariates included maternal age (continuous), BMI (continuous), menarcheal age (continuous), parity status (primiparous or multiparous), educational status (<high school, high school, >high school), occupational status (farm work, routine job, temporary job, unemployed), maternal residence (rural v. urban), child' sex and recruiting year (<2010, ≥2010). Maternal smoking status, alcohol drinking status, history of diabetes, hypertension and heart disease were not included in the statistical model as their prevalence was extremely low (0·71 % for the current alcohol drinker, <0·2 % for the other four covariates) in this population and had negligible influence on the associations. Among the users of folic acid, initiation of supplement use before or after conception was analysed separately to examine their potentially differential associations with pregnancy outcomes. In addition, the associations between frequency of folic acid use and pregnancy outcomes were explored. For each outcome, effect modification was examined by adding an interaction term of folic acid with a potential covariate, such as maternal age, BMI, menarcheal age, parity status, educational status, occupational status, maternal residence, child's sex and recruiting year.
A two-tailed P value < 0·05 was regarded as statistically significant. All the statistical analyses were performed using STATA software version 12 (StataCorp LP).
Results
Population characteristics and folic acid supplementation
Among all the participants, the prevalence of folic acid supplementation was 24·9 %. Post-conceptional folic acid use showed higher prevalence (14 %) compared with preconceptional folic acid use (10 %). When stratified by the recruiting year, the prevalence of folic acid supplementation ranged from 7·6 to 24·2 % during the 11 years from 1999 to 2009, and it increased to 48·7 % in 2010 and to 67·2 % and 64·6 % in 2011 and 2012, respectively (Fig. 1) .
Folic acid users, compared with non-users, were more likely to be within the age range of 26-30 years, primiparous, had a menarcheal age <14, had higher educational level and were living in urban areas ( Table 1 ). The prevalence of PTB and SGA birth was 3·48 and 9·20 %, respectively. The prevalence of PTB was similar among non-users (3·49 %), pre-conceptional folic acid users (3·34 %) and post-conceptional folic acid users (3·51 %). Among non-users, the prevalence of SGA birth (9·39 %) was higher than that in pre-conceptional (8·57 %) and post-conceptional folic acid users (8·68 %).
Folic acid supplementation and preterm birth
Folic acid supplementation was associated with 5 % lower risk of PTB (adjusted relative risk (RR) = 0·95; 95 % CI 0·90, 1·01) ( Table 2) . When separated by the timing of folic acid introduction, pre-conceptional folic acid supplementation was associated with 8 % decreased risk of PTB (adjusted RR 0·92; 95 % CI 0·85, 1·00). In addition, a significant dose-response relationship between folic acid use and risk of PTB was found in the pre-conceptional folic acid users (P trend = 0·032), but not in post-conceptional users (Table 3) . Folic acid use showed no significant interaction with any covariate on PTB risk.
Folic acid supplementation and small-for-gestational-age birth A significant inverse association between folic acid supplementation and risk of SGA birth was observed (RR 0·91; 95 % CI 0·88, 0·94) in the crude model. The inverse association did not change remarkably in the multivariable model, and 12 % lower risk of SGA birth (adjusted RR 0·89; 95 % CI 0·80, 1·00) was observed. The protective association of folic acid supplementation against SGA birth was observed only when folic acid was taken pre-conceptionally (adjusted RR 0·81; 95 % CI 0·70, 0·95), and no significant association (adjusted RR 0·95; 95 % CI 0·83, 1·09) was observed among post-conceptional folic acid users (Table 2) . Consistently, a significant dose-response association was observed only among the pre-conceptional folic acid users (P trend = 0·046) ( Table 3) .
A significant interaction between folic acid use and recruiting year for the risk of SGA birth was observed (P interaction = 0·014) ( Table 4 ). The inverse association between folic acid supplementation and risk of SGA birth was only observed in participants recruited before 2010 (adjusted RR 0·81; 95 % CI 0·71, 0·93). Furthermore, in participants recruited before 2010, the protective association of folic acid use against SGA birth was only observed in participants who took the supplementation pre-conceptionally (adjusted RR 0·71; 95 % CI 0·58, 0·88).
Discussion
The present study suggested that folic acid supplementation was associated with lower risk of PTB and SGA birth in women who started taking folic acid supplements before conception, but not in those who started taking the supplements after conception. The present study has provided, so far, the largest sample size to examine the relationship between folic acid supplementation and PTB and SGA birth in a Chinese setting. The present results provide important and valuable information for the prevention of PTB and SGA in the Chinese populations.
Pre-conceptional folic acid use was suggested to be inversely associated with the risk of PTB or SGA birth in a number of prospective cohort studies (9, 14, 17, 18, 21, 22) . In a cohort of 34 480 US women who pre-conceptionally started folic acid supplementation, there was a 50-70 % reduction in the incidence of early spontaneous PTB (9) . In another cohort of 6353 women in the Generation R Study from the Netherlands, women who pre-conceptionally started taking folic acid supplements showed a 60 % reduction of SGA birth risk compared with nonusers (14) . In a recent cohort study in China, peri-conceptional use of folic acid supplementation was associated with 30 % decreased risk of spontaneous PTB. These studies are in line with the present study, showing that the protective association of folic acid supplements against PTB or SGA birth only existed among those who started taking the supplements pre-conceptionally, but not in those who started taking the supplements after conception. It appeared that the protective association of pre-conceptional folic acid supplementation in the present study was much weaker compared with the aforementioned studies. It may be because of the residual confounding factors in the present study, as it involved participants from 1999 to 2012. During this time period, diet, lifestyles and certain socio-economic statuses may have changed remarkably due to the rapid economic growth across the country. Among pre-conceptional folic acid users, it appeared that less frequent folic acid use was much stronger related to SGA than more frequent supplement use. Misclassification of folic acid supplement use may contribute to such results. In addition, among the category ' <15 cap/month', the number of study participants was rather small, which may not provide sufficient statistical power to examine the associations. The mechanisms behind the relationship between folic acid supplementation and PTB and SGA birth are not fully understood. Folate is a critical B vitamin, which acts as a one-carbon donor that is implicated in biological pathways of many cellular processes such as cell multiplication, apoptosis and intracellular signalling, as well as fetal and placental growth and development (1) . Furthermore, folic acid supplementation may affect fetal growth by regulating the folate-dependent homocysteine pathway. Hyperhomocysteinaemia was associated with decreased fetal growth and placental vasculopathy (23) , whereas high folate status was associated with lower homocysteine level (24) . Consistent with previous reports by Timmermans et al. (14) , the present study found a significant inverse association between folic acid use and risk of common adverse pregnancy outcomes when taken pre-conceptionally, but not post-conceptionally. This may be because pre-conceptional exposure to folic acid may exert some additional benefits to fetal growth via epigenetic modification (25, 26) . Since late 2009, rural Chinese women of child-bearing age were given free folic acid supplements (400 mg/d) from the Government as part of a public health project initiated by the Ministry of Health in China. As a result of this policy, the prevalence of folic acid supplementation in the present study population increased from 24·2 % in 2009 to 48·7 % in 2010. The prevalence continued to increase to 67·2 and 64·6 % in 2011 and 2012, respectively. Interestingly, a significant interaction between folic acid use and recruiting year for SGA birth was observed. This may reflect some residual confounders in the present study. Indeed, the initiation of the new policy may have increased the health consciousness of women of child-bearing age and reduced other risk factors of adverse pregnancy outcomes, thereby attenuating or even eliminating the inverse association of folic acid supplements with SGA birth. On the other hand, women who used folic acid supplements before they were free may be more health-conscious and associated with healthier lifestyles or better economic status, thereby strengthening the inverse association of folic acid supplements with SGA birth. Nevertheless, no interaction between folic acid supplementation and recruiting year for PTB was observed. Therefore, the influence of the free folic acid distribution policy on the association between folic acid supplementation and adverse pregnancy outcomes warrants further investigation.
The prevalence of folic acid supplementation found in this study is in agreement with some other studies in China (27) (28) (29) (30) (31) . Between 2002 and 2004, 483 rural women were recruited to investigate the blood folate concentrations and the status of folic acid supplementation in Shanxi Province in China. This survey found that 47·6 % of the women had erythrocyte folate deficiency, and <10 % reported having ever taken folic acid supplements during their current pregnancy (27) . In another cross-sectional study of 1338 women of child-bearing age who were recruited in 2008 in Shanghai, only 14·9 % of the subjects took folic acid supplements at least once per day, whereas 74·3 % of them had never taken it (28) . In addition, within this Shanghai population, nearly half of them did not know that folic acid should be taken before pregnancy.
We noticed that the prevalence of PTB in the present study was much lower than that reported by a recent WHO report (7·1 %) (32) . However, accordingly to a recent global report on PTB and still birth (33) , the prevalence of PTB in China has decreased from 7·5 % in 1981-1982 to 3·5 % in 1998 (34) . Another large-scale study (35) , based on 542 923 women in ten counties from South and North China, suggested that the PTB rate declined steadily from 1993 to 2005, with an overall PTB rate of 4·49 % during 1993 and 2005 and 3·62 % in 2005. A more recent large study, involving 26 611 pregnancies in Southeast China's Jiangsu Province, also found that the PTB prevalence ranged from 2·6 to 2·9 % in urban and rural areas (36) . Therefore, our report about the prevalence of PTB was consistent with these studies. The reason for the inconsistency between the WHO report and present study and other aforementioned studies is not clear and needs further clarification. There are several strengths to the present study. First, to the best of our knowledge, this study was the largest prospective cohort study to comprehensively examine the association between folic acid supplementation and risk of PTB and SGA in Chinese populations. The large sample size gave us sufficient power to examine the topics of concern. Second, the present study was a population-based prospective cohort, which would have minimised the influence of selection or recall bias. In addition, almost all the participants were of Han ethnicity and shared similar lifestyle and dietary patterns, which would have reduced the residual confounding factors.
Several limitations are present for this study. First, we did not collect information on multivitamin use, which is a major limitation of the present study. Indeed, use of folic acid and multivitamin might be highly correlated and influence the associations of folic acid use with birth outcomes. Second, our participants were recruited from Southeast China, and the generalisability of the present results to other regions of China may be inappropriate. Nonetheless, the prevalence of folic acid supplementation and other maternal characteristics in the present study were consistent with populations of other regions in China (27) (28) (29) (30) . This suggested that our population could, to some extent, represent women from other regions. Third, the observational nature of the study design made it subject to some residual confounding factors. Fourth, there may be misclassification of folic acid supplements, especially for the frequency of folic acid use, and potential sporadic folic acid use. In addition, we did not collect information on the actual dose of folic acid supplements. In this study, we assumed that 400 mg tablets of folic acid supplements were used by the present population, as after 2009 folic acid supplements were freely available in the form of 400 mg tablets. This dose was also widely recommended for women of child-bearing age or during pregnancy in China before 2009. Fifth, we did not measure the duration of folic acid supplementation of the folic acid users, and therefore could not examine the influence of folic acid use duration on birth outcomes. Finally, recall and outcome misclassification may exist -for example, gestational age was based on self-reported last normal menstrual period, which is known to be error prone.
In conclusion, the present study suggests an inverse association of pre-conceptional folic acid supplementation with lower risk of PTB and SGA birth. Further studies in this field are warranted to replicate these findings. The authors declare that there are no conflicts of interest.
